Search

Displaying results 5071 - 5080 of 10000 in total
  1. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    Tosedostat is an inhibitor of the M1 family of aminopeptidases, in particular PuSA, and LTA4 hydrolase. … It entered the clinical trial in patients with haematological malignancies.

  2. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  3. Drug

    VSF-173

    go.drugbank.com/drugs/DB05753
    Investigational

    VSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. … It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.

  4. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    In an effort to improve [haloperidol]'s pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic … It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518].

    Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor Antagonists
  5. Drug

    Dehydrocholic acid

    go.drugbank.com/drugs/DB11622
    Approved

    Dehydrocholic acid is a synthetic bile acid that was prepared from the oxidation of cholic acid with chromic acid [A33022]. It has been used for stimulation of biliary lipid secretion. … The use of dehydrocholic acid in over-the-counter products has been discontinued by Health Canada.

  6. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. … PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

  7. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  8. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). … As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options.

  9. Drug

    Edetate disodium anhydrous

    go.drugbank.com/drugs/DB14600
    ApprovedInvestigationalVet approved

    Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.[A204275]

  10. Drug

    XTL-001

    go.drugbank.com/drugs/DB05405
    Investigational

    XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected